Interview of Stanislas Veillet, CEO of Biophytis on La Bourse ou la Vide.com (in French).
Biophytis Identifies False Report Regarding COVA StudyRead the Press Release
Stanislas Veillet, CEO of Biophytis, reviews the company’s latest news in this interview with Laurent Grassin from Journal des Biotechs, covering listing on Nasdaq, Covid-19 clinical studies, expected clinical data in sarcopenia and the legal case with Negma. You can see the interview here
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd